厄洛替尼联合DC/CIK在晚期非小细胞肺癌维持治疗中的作用

  目的  本实验研究厄洛替尼（Erlotinib，特罗凯）联合DC/CIK生物免疫治疗和单用特罗凯在晚期非小细胞肺癌维持治疗中的作用。  方法  收集56例Ⅲb、Ⅳ期的非小细胞肺癌患者，其一线治疗为4个周期的含铂两药方案化疗，将疗效达到稳定或以上患者随机分为两组。一组给予特罗凯和DC/CIK生物免疫治疗，另一组给予特罗凯治疗，评价两组的无进展生存（PFS）时间及不良反应。  结果  两组的PFS分别是5.30个月（95%CI 5.02~5.58）和4.42个月（95%CI 4.20~4.63）（P < 0.05）。两组的不良反应主要为皮疹和腹泻。联合组在DC/CIK输注过程中2例出现胸闷，3例出现乏力，3例出现发热。  结论  特罗凯联合DC/CIK在晚期非小细胞肺癌维持治疗中是一种安全有效的方法。 

The Effects of Maintenance Therapy Combining DC/CIK and Erlotinib on Patients with Advanced Non-small Cell Lung Cancer

  Objective  To evaluate the effects of maintenance therapy using a combination of dentritic cells (DC) /cytokine induced killer cells (CIK cells) and erlotinib on patients with advanced non-small cell lung cancer (NSCLC).  Methods  We used data of 56 cases with Stage-Ⅲb or Ⅳ NSCLC, who underwent 4 cycles of platinum-based two-drug chemotherapy and achieved a status of stable disease or much better condition. The patients were randomized into 2 groups, i.e., Group One, which received a biological immunotherapy using a combination of erlotinib and DC/CIK cells, and Group Two, which was given erlotinib therapy alone. The main end point was progression-free survival (PFS), while the adverse reactions comprised the second end point.  Results  The PFS of both groups were 5.30 months (95%, CI 5.02-5.58) and 4.42 months (95%, CI 4.20-4.63), respectively, P < 0.05. The untoward reactions of both groups were rashes and diarrhea. In Group One, chest distress was found in 2 cases, acratia in 4, and fever in 3 during DC/CIK infusion.  Conclusion  The maintenance treatment, which combines erlotinib with DC/CIK cells is a safe and effective method in treating advanced NSCLC.